IPSC

#3144
Century Therapeutics, Inc. - Common Stock
2.0 3 USD
-0.09%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
2.03
2.03
Jahresspanne
0.44
3.03
Tagesänderung
-8.97%
Monatliche Änderung
-0.98%
6 month change
-9.38%
Jahresänderung
+314.29%
Vorheriger Schlusskurs
2.2 3
Open
2.0 3
Tief
2.0 3
Hoch
2.0 3
Volumen
34
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Century Therapeutics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Century Therapeutics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Century Therapeutics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Century Therapeutics, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Century Therapeutics, Inc. current report, Q1 FY2026
8-K

Century Therapeutics, Inc. current report, Q1 FY2023

Full document

Century Therapeutics, Inc. Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Century Therapeutics, Inc. (Nasdaq: IPSC) on January 9, 2023, covering events occurring on January 5, 2023. The Company is a Delaware corporation focused on developing therapies for rare diseases. The filing serves to disclose regulatory updates and strategic operational changes.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses on strategic planning rather than the disclosure of specific financial statement line items for the period.

Material Changes and Strategic Actions

  • Portfolio Prioritization: On January 5, 2023, the Company announced a plan for internal portfolio prioritization.
  • Cash Runway Extension: The primary objective of the prioritization plan is to extend the Company's cash runway into 2026.
  • Investor Presentation Update: The Company updated an investor presentation originally dated January 9, 2022, which is attached as Exhibit 99.1.

Guidance, Outlook, and Risks

Management's outlook centers on the execution of the portfolio prioritization strategy to ensure financial sustainability through 2026. The filing notes that the updated investor presentation and press release are furnished under Regulation FD and Item 8.01 but are not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting their incorporation by reference in other filings unless explicitly stated.

Investor Verification Checklist

  • Review Exhibit 99.2 (Press Release dated January 5, 2023) for specific details on which assets are being deprioritized or discontinued.
  • Examine the updated investor presentation (Exhibit 99.1) for revised clinical timelines and financial projections.
  • Verify the Company's current cash balance and burn rate in the most recent 10-Q or 10-K to assess the feasibility of the 2026 runway target.
  • Confirm whether the portfolio changes impact any existing partnership agreements or milestone obligations.

Nachrichten